首页 News 正文

Novartis Pharmaceuticals announced on December 6th that the US Food and Drug Administration (FDA) has approved the launch of its Fabhalta (iptacopan), which is the first FDA approved oral monotherapy for the treatment of adult paroxysmal nocturnal hemoglobinuria (PNH). Phase III clinical trials have shown that this therapy helps to increase patients' hemoglobin levels without the need for blood transfusions. The therapy is expected to be launched in the United States in December.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

阿豆学长长ov 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    27